Cancer-Associated Thrombosis: Risk Assessment, Prevention, and Treatment

The risk of developing venous thromboembolism (VTE) is four to seven times higher in patients with cancer than in those without. At JADPRO Live 2022, presenters discussed risk factors and assessing patients for VTE, as well as how to protect patients against VTE in both the inpatient and outpatient...

Descripción completa

Detalles Bibliográficos
Autores principales: Halsema, Keri, Mcmahon, Brandon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184841/
https://www.ncbi.nlm.nih.gov/pubmed/37197728
http://dx.doi.org/10.6004/jadpro.2023.14.3.6
_version_ 1785042221448298496
author Halsema, Keri
Mcmahon, Brandon
author_facet Halsema, Keri
Mcmahon, Brandon
author_sort Halsema, Keri
collection PubMed
description The risk of developing venous thromboembolism (VTE) is four to seven times higher in patients with cancer than in those without. At JADPRO Live 2022, presenters discussed risk factors and assessing patients for VTE, as well as how to protect patients against VTE in both the inpatient and outpatient clinic settings. They reviewed selecting an appropriate anticoagulation treatment, including the choice of agent and duration of treatment for the patient with cancer, and finally the steps needed to assess and treat patients experiencing therapeutic anticoagulation failure.
format Online
Article
Text
id pubmed-10184841
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-101848412023-05-16 Cancer-Associated Thrombosis: Risk Assessment, Prevention, and Treatment Halsema, Keri Mcmahon, Brandon J Adv Pract Oncol Meeting Reports The risk of developing venous thromboembolism (VTE) is four to seven times higher in patients with cancer than in those without. At JADPRO Live 2022, presenters discussed risk factors and assessing patients for VTE, as well as how to protect patients against VTE in both the inpatient and outpatient clinic settings. They reviewed selecting an appropriate anticoagulation treatment, including the choice of agent and duration of treatment for the patient with cancer, and finally the steps needed to assess and treat patients experiencing therapeutic anticoagulation failure. Harborside Press LLC 2023-04 2023-04-01 /pmc/articles/PMC10184841/ /pubmed/37197728 http://dx.doi.org/10.6004/jadpro.2023.14.3.6 Text en © 2023 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Halsema, Keri
Mcmahon, Brandon
Cancer-Associated Thrombosis: Risk Assessment, Prevention, and Treatment
title Cancer-Associated Thrombosis: Risk Assessment, Prevention, and Treatment
title_full Cancer-Associated Thrombosis: Risk Assessment, Prevention, and Treatment
title_fullStr Cancer-Associated Thrombosis: Risk Assessment, Prevention, and Treatment
title_full_unstemmed Cancer-Associated Thrombosis: Risk Assessment, Prevention, and Treatment
title_short Cancer-Associated Thrombosis: Risk Assessment, Prevention, and Treatment
title_sort cancer-associated thrombosis: risk assessment, prevention, and treatment
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184841/
https://www.ncbi.nlm.nih.gov/pubmed/37197728
http://dx.doi.org/10.6004/jadpro.2023.14.3.6
work_keys_str_mv AT halsemakeri cancerassociatedthrombosisriskassessmentpreventionandtreatment
AT mcmahonbrandon cancerassociatedthrombosisriskassessmentpreventionandtreatment

Ejemplares similares